This article was originally published by Nila on July 15, 2026. Read the original version here
An evidence-graded, community-powered menopause platform built by a survivor. Now on web and iOS; Android in closed testing.
VICTORIA, BC, July 15, 2026. Nila’s Android app has entered closed testing on Google Play, with production review to follow once Play Console requirements are met, three weeks after the iOS app launched to a 5-star early rating. The average time between a woman’s first perimenopause symptom and an actual diagnosis is 4.6 years. In Canada, unmanaged menopause symptoms now cost an estimated $3.5 billion a year: $3.3 billion in income women lose to reduced hours, reduced pay, or leaving the workforce entirely, and $237 million in lost employer productivity. Nila is closing that gap.
What Nila is
Nila is a single platform. The chat is one doorway into a moderated community, an evidence-graded research library, symptom and treatment guides scored for evidence quality, and a private daily check-in, each a full part of the platform.
The platform also includes guides written for the people around her. Five separate guides sit alongside the clinical content, free and unlocked: one for a partner, one for her kids (whether teenagers still at home or grown and gone), one for her closest friend, one for the adult child of an already postmenopausal mother, and a couples conversation guide with six scripted openings. Premium members can also generate a short, tailored version in plain language to send to a specific person, drawn from their own chat history.
Why now
British Columbia began offering free public coverage of hormone replacement therapy in March 2026, and Western Canada’s first Complex Menopause Clinic opened at BC Women’s Hospital in 2025. The FDA removed its black-box warning for systemic estrogen in November 2025. Globally, an estimated 1.2 billion women will be in or past menopause by 2030, roughly one in seven people on the planet.
The investment picture hasn’t caught up. Roughly 6% of private healthcare investment goes to women’s health, even after a record US$2.6B year in 2024 (SVB, 2025). The imbalance is stark at the condition level: between 2019 and 2023, companies working on erectile dysfunction raised US$1.24 billion, while endometriosis, a condition affecting an estimated 190 million people worldwide, with a 7- to 10-year diagnostic delay, drew just US$44 million (npj Women’s Health, 2024). Less than 1% of healthcare funding in that window went to women-specific conditions (McKinsey Health Institute, 2025), and women weren’t even required in US clinical trials until 1993, so most legacy safety and efficacy data were built on male bodies.
The FemTech market is projected to grow from US$39B in 2024 to US$97B by 2030, and the untapped menopause medication market alone is estimated at US$120B–US$230B annually. McKinsey and the WEF put the prize for closing the broader women’s health gap at US$1 trillion in GDP and roughly 137 million more women in full-time work by 2040, about $3 returned for every $1 invested. A 2026 analysis from the World Economic Forum, Kearney Health Institute, the Gates Foundation, and Wellcome Leap specifically identified menopause as under-resourced relative to its disease burden, mapping the gap across funding, evidence, and product pipelines. Virtual menopause clinics have validated that people will pay for care; Nila is positioned to own the larger surface around it (community, research, and guidance) at a fraction of the cost, for the populations those clinics structurally don’t serve.
Built for whom the research left out
Nila organizes its content into 20 named pathways based on how menopause actually arrives in someone’s life, with several built for groups underrepresented in both research and the mainstream conversation. Vasomotor symptoms last a median of 10.1 years for Black women, versus 7.4 years overall, and much of the landmark research hasn’t reflected that. One in three women reaches menopause during or after cancer treatment. Estrogen quietly regulates dopamine, focus, and sensory filtering, so women managing ADHD or autism can find that strategies that worked for decades suddenly stop working. Nila has dedicated pathways for each, plus trans and non-binary hormone journeys, sole carers, and shifts in identity and mood, along with a standalone research-gaps page that names, with sources, where the evidence base is thinnest. The full list of who Nila is written for is laid out at hellonila.com/who-this-is-for.
What’s in it
The research library holds 17 curated shelves and 65 symptom guides across seven body systems, each graded for evidence quality and dated. The treatments section spans six clinical areas, with in-depth explainers on the WHI study, cancer-risk concepts, and body-identical versus bioidentical hormones. A 110-entry relief finder and a verified practitioner directory (filterable by modality, region, and lived-experience affirmation) round out the toolkit. Nila (hellonila.com) launched on May 21, 2026; its iOS app followed on June 30, and the Android app is now in closed testing. Membership is freemium: the community, guides, and daily check-in are free to join, with a paid Premium tier for individuals and paid seats for employers.
Two months in, by the numbers
Nila launched on May 21, 2026. In the roughly 60 days since, hellonila.com has drawn about 4,100 visitors and 19,500 pageviews, with daily traffic climbing from around 25 visits at launch to a sustained 50 to 85 a day through June and July, and single days already topping 119. The community has grown to 119 members, with a third of them joining in the past 30 days, and has posted 44 threads and 78 comments. Members have opened 92 chat sessions with Nila’s AI companion, exchanging more than 500 messages, alongside symptom logs, weekly check-ins, and saved items in personal stacks.
Behind it: 431 research articles, built and edited by a single founder in under three months; seven verified practitioners now listed in the directory; and a partnership inquiry underway. The newsletter, launched July 4, already has 602 subscribers. The iOS app carries a 5-star rating from its early reviewers; the Android app is in closed testing. Nila is a member of Femtech Canada and The Menopause Society, and is listed in the FemTech Observatory 2026.
Five promises, written down
- No data is ever sold: not now, not anonymized, not if the company is acquired.
- Sources are cited and dated, with evidence grades updated as research changes.
- Sponsorships are disclosed inline, never in fine print.
- Counselling, treatment, identity, and crisis pages carry no sponsorship, ever.
- Pro-information: editorially independent of any treatment agenda.
For employers
Nearly half of women say menopause symptoms disrupt their work. In the UK, 1 in 10 women have left a job over symptoms (Fawcett Society), and 73% of UK workplaces offer no menopause support at all (CIPD). In the US, unmanaged symptoms cost an estimated $26.6 billion annually (Mayo Clinic Proceedings, 2023); in the UK, absenteeism alone costs an estimated £11 billion annually (NHS Confederation/CREATE, 2025). In Canada, the total is $3.5 billion annually: $3.3 billion borne directly by women through reduced hours, reduced pay, or leaving the workforce, and $237 million in lost employer productivity, roughly 540,000 workdays a year.
Nila’s free workplace toolkit ( hellonila.com/work-toolkit ) includes seven print-ready templates built ahead of the UK’s incoming Employment Rights Act 2025 requirement for a Menopause Action Plan. Nila for Teams offers self-serve Premium access for employees at CAD $69 to $109 per seat per year for teams of 10 to 250-plus, a fraction of the £15 to £40 per employee per month charged by comparable clinical-care marketplaces. Individual employee data is never shared with employers, ever, not even in aggregate below five seats.
About Nila (backgrounder)
Nila is a freemium community, evidence-graded research library, and care toolkit for perimenopause and menopause (naturally, surgically, or medically induced), founded in Victoria, BC. The community, guides, and daily check-in are free to join. Premium unlocks the full research library, daily symptom tracking with doctor-ready exports, structured programmes, and members-only community rooms for CAD $12.99/month or $129/year; employers can buy Premium seats for staff through Nila for Teams. Nila is a member of Femtech Canada and The Menopause Society, and is listed in the FemTech Observatory 2026.
Erin Beattie
Erin Beattie is the editor, researcher, developer, founder, and funder behind Nila. Her path to building it began eighteen years earlier, with undiagnosed endometriosis. In September 2023, she was diagnosed with hormone-positive breast cancer. Treatment, including Tamoxifen and Zoladex, deliberately suppressed her estrogen, inducing chemical menopause. A hysterectomy prompted by MSH2 gene flags (a marker for Lynch syndrome) followed; that surgery is where her endometriosis was finally confirmed, and it triggered full acute surgical menopause. Because her cancer is hormone-positive, systemic HRT remains a genuinely open question for her; she currently uses local vaginal estrogen, with research on further options still evolving. That gray zone, neither cleared for hormone therapy nor ruled out from it, is central to why Nila is built for more than one kind of menopause story.
“Most of what’s out there treats menopause as one story. Nila is built for the version that arrived after surgery, after cancer, alongside ADHD, or outside the timeline anyone prepared you for.”Erin Beattie, Founder
Why women’s health, why Nila, why now
Nila enters a category that is finally being priced honestly. Roughly 6% of private healthcare investment goes to women’s health, against a FemTech market projected to grow from US$39B in 2024 to US$97B by 2030. The untapped menopause-medication market alone is estimated at US$120–230B/year. 450 million women are currently in or past menopause; 1.2 billion will be by 2030. Women weren’t required in US clinical trials until 1993, so most legacy evidence was built on male bodies. McKinsey estimates closing the women’s-health gap is a US$1T+ GDP opportunity by 2040.
Virtual menopause clinics (US$99–$379/month, regional, prescription-bound) have validated the category. Nila owns the bigger half: moderated community, evidence-based research library, symptom and treatment guides, and a private companion at CAD $12.99/month, globally, for the populations clinics structurally don’t serve (induced menopause, post-cancer, neurodivergent, trans and non-binary, women of colour, sole carers).
Sources: SVB Innovation in Women’s Health 2025; Grand View Research FemTech market; NIH ORWH; McKinsey Health Institute / WEF, Closing the Women’s Health Gap (2024).
Contact
For media inquiries — interview requests, review access, fact-checks, and higher-resolution assets — as well as funder conversations, employer pilots, and clinical or research partnerships. Founder available for intro calls.